# SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

> **NCT00522951** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 165 (actual)

## Conditions studied

- Brain Metastases

## Interventions

- **DRUG:** Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- **DRUG:** Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- **DRUG:** ProHance

## Key facts

- **NCT ID:** NCT00522951
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2017-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522951, "SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00522951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*